Date: 2021-09-21
Type of information: Company acquisition
Acquired company: Comet Therapeutics (USA-MA)
Acquiring company: VectivBio (Switzerland)
Amount: -
Terms:
Details: The CoMET small molecule platform aims to treat a large group of life-threatening IMDs, which are severe genetic disorders caused by congenital defects of metabolism fundamental to energy generation and the survival of cells. While each IMD is individually rare, collectively, they occur in 1 in 800 births, affect over 75,000 people in the United States and Europe, and are one of the leading causes of death from non-acquired causes in children. The genetic defects causing IMDs disrupt energy production, promote the accumulation of toxic metabolites, and result in the dysregulation of Co-enzyme A (CoA), a core component of many metabolic pathways. The CoMET platform is designed to target these critical cellular dysfunctions by utilizing a stabilized CoA precursor backbone to supply functional CoA and carry tailored intermediary metabolite cargos to address specific underlying conditions. This modular technology can potentially treat multiple previously untreatable IMDs by systemically and intracellularly delivering medicines that restore cellular function.
Related: Rare diseases